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281 Home parenteral nutrition (HPN) in malnourished cystic ﬁbrosis
(CF) patients: A safe and effective nutritional therapy
A. Lezo1, B. Santini2, D. Sabet2, E. Bignamini3. 1Pediatric Hospital Citta` della
Salute e della Scienza, Clinical Nutrition, Turin, Italy; 2University of Turin,
Clinical Nutrition, Turin, Italy; 3Pediatric Hospital Citta` della Salute e della
Scienza, Pulmonology, Turin, Italy
Objectives: Evaluation of efﬁcacy and complication’s rate of HPN in severely
malnourished CF patients who failed to improve their nutritional status with dietetic
counselling and oral integration.
Methods: We retrospectively analyzed a case series of 7 CF patients reporting clin-
ical and nutritional data, HPN characteristics and complication’s rate. 6/7 patients
were referred to lung transplantation.
Results: Patients were all females with pancreatic insufﬁciency, mean age 16.3 yrs
(11.5–21.8), FEV1 <35% predicted (6/7), mean BMI Z-score −3.8 prior the HPN.
The decision to start the HPN was taken on the basis of clinical status, the reduction
of BMI Z-score despite the intensive dietetic treatment during the previous year
and the high infusional needs due to reacutizations. The central venous catheters
(CVC) were Port-a-Cath (2/7) and PICC (5/7). Mean HPN duration was 12.4 months
(4−27), with night-time infusions, 5−6 days/week. Weaning from PN (6/7) was due
to lung transplantation (4/7) and to achieved adequacy of oral intakes (2/7). HPN
provided 125% of Basal Energy Expenditure with 35% (29−40) of total energy
provided by lipids. BMI z-score increased 2.4 folds (−3.8 to −1.6), there were
no short-term complications and any modiﬁcation of daily activities on HPN.
CVC related infection was 0.38/1000 infusion days (a single case in a 7 years
old Port-a-Cath). Two mechanical complications didn’t require hospitalization or
total anaesthesia. All patients showed adequate vitamin and bone status without
metabolic complications of HPN.
Conclusion: HPN may be valid and ﬂexible nutritional therapy in malnourished
CF patients shaping on the whole therapeutic process.
282 Evaluation of nutrition education in a group of children with
moderate to severe cystic ﬁbrosis (CF)
E. Owen1, M. Bryon2, A. Prasad3, R. Suri3. 1Great Ormond Street Hospital
for Children NHS Foundation Trust, Dietetics, London, United Kingdom; 2Great
Ormond Street Hospital for Children NHS Foundation Trust, Paediatric Psychology,
Psychosocial and Family Services, London, United Kingdom; 3Great Ormond
Street Hospital for Children NHS Foundation Trust, Cystic Fibrosis Unit, London,
United Kingdom
Objective: To evaluate patients’ nutritional knowledge before and after a short
educational programme.
Methods: 15 pancreatic insufﬁcient children (5−15 years, median age 11), who
were enrolled on a joint physiotherapy and dietetic project, completed a 12-item
multiple choice nutrition quiz. Questions were asked on diet, pancreatic enzymes
and vitamins, to assess baseline knowledge and identify areas to educate. Age-
appropriate activities on these topics were designed with accompanying written
information. Individualised interactive teaching sessions were delivered as needed
by the dietitian to the children 1−2 monthly over 12 months (ward, outpatient or
home visits). The quiz was repeated at the end (n = 13). A patient satisfaction survey
was completed (n = 12) at the end.
Results: Baseline scores indicated gaps in knowledge (mean 8.7). Scores at the end
improved (mean 9.8). Older children (11 years) showed a greater improvement,
however the mean score for younger children (5−10 years) remained similar pre and
post education. Results of the satisfaction survey indicated that sessions helped the
children understand their diet better and doing practical activities helped them learn
about CF. There was a clear indication that home was not the preferred location for
dietetic intervention.
Conclusions: Nutrition education was positively received by patients. Staged one-
to-one sessions could be incorporated into the wider clinic on a scheduled outpatient
basis. Reﬁnement of the quiz could allow it to be used as a screening tool to assess
those who would most beneﬁt from education and speciﬁc topics. Younger children
need more regular teaching sessions to retain knowledge.
283 Evaluation of a novel behavioural intervention programme (BIP)
to modify mealtime behaviour for young children with cystic
ﬁbrosis
A.J. Coates1, C. Harte1, D.S. Urquhart1. 1Royal Hospital for Sick Children,
Edinburgh, United Kingdom
Background: Parents of children with CF report more problematic mealtime
behaviours and high levels of parental anxiety around mealtimes.
Objective: To evaluate a psychologist/dietitian led BIP aimed at modifying meal-
time behaviour in children with CF.
Methods: Parents of 6 pancreatic insufﬁcient children with CF aged 2−6 years
attended a BIP consisting of 4×2 hour weekly sessions +1 follow up session
5 weeks later. Content included parenting pyramid framework, use of praise
to maximise effect at mealtimes, boundary-setting, increasing food variety, and
managing enzyme replacement therapy.
Parents completed questionnaires at the end of the BIP and 6 months later.
Body Mass Index z-score (BMIZ) was calculated at baseline, 3 and 6 months after
BIP completion.
Results: All parents completed the BIP and evaluation. Session attendance
was 93%.
Evaluation 6 months post-BIP
100% parents (6/6) felt more conﬁdent about managing mealtime behaviour and
67% (4/6) felt a lot more conﬁdent
83% (5/6) found mealtimes less stressful
83% (5/6) felt their child enjoyed mealtimes more
Parents unanimously reported (open question, no prompt boxes) that the most
helpful aspect of the BIP was the opportunity to share experiences.
BMIZ at 3 months compared with baseline was increased (p = 0.002) although this
was not sustained at 6 months (p = 0.38).
Conclusions: A pilot BIP for parents of children with CF shows promising results in
modifying mealtime behaviour and reducing stress. BMIZ is signiﬁcantly increased
at 3 months follow up but not 6 months. A key ﬁnding from the study is the value
that parents place on peer support and the opportunity to share experiences within
the framework of an educational programme.
284 The development of guidelines for the use of megestrol acetate
(Megace®) as an appetite stimulant in adults with cystic ﬁbrosis
J. Al-Siaidi1, A. Keele1, K. Bateman1. 1Bristol Adult Cystic Fibrosis Centre,
Bristol, United Kingdom
Objectives: Poor nutritional status remains a challenge in some CF patients,
contributing to decline in lung function and premature death. In the USA megestrol
acetate (MA) is licensed for use as an appetite stimulant in HIV, AIDS and cancer.
Small studies with CF patients have shown weight gain but there is insufﬁcient
evidence to routinely recommend use. Following trials of MA with patients failing
to respond to, or declining conventional therapies we developed guidelines for the
use of this unlicensed drug, considering safety and efﬁcacy.
Methods: We evaluated use of MA in 5 patients. 4 patients had CFrelated diabetes,
3 patients were using overnight feeding. Initial dose was 320mg/day; duration
of therapy ranged from 4 weeks to 10 months except 1 patient taking 4 week
courses alternate months long term. 4 patients gained weight and reported signiﬁcant
improvement in quality of life; 1 patient reported increased appetite but gained no
weight. Side effects were: adrenal insufﬁciency (permanent in patient taking MA
longterm), impotence, hyperphagia, abdominal bloating. Dose adjustment suggested
efﬁcacy at lower dose in most patients. Following literature review, and consultation
with other users of MA, guidelines were produced regarding identiﬁcation of
patients, dosage, duration of treatment and monitoring of effects, including adrenal
suppression.
Conclusion: Use of MA was associated with improvement in nutritional status
and quality of life in patients not responding to conventional therapy but is not
without side-effects. We recommend an initial dose of 160mg/d. The development
of guidelines ensures appropriate use of MA and monitoring of side-effects.
